中風治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球卒中治療市場規模達1,66億美元，預計2034年將以8.2%的複合年成長率成長，達到364億美元。這主要得益於老齡人口的成長，以及肥胖、高血壓、久坐不動的生活方式以及糖尿病等慢性疾病等風險因素的增加。老齡化人口尤其容易患卒中，這導致對先進藥物治療的需求增加。同時，公眾健康意識的增強以及政府在早期診斷和預防方面的舉措加強，正在加速卒中治療的普及。

製藥公司投資研發，專注於新型生物製劑、基因療法和標靶藥物，旨在改善臨床療效。個人化醫療正成為一個備受關注的關鍵領域，有助於實現更精準、更有效的治療方法。中風治療藥物涵蓋從抗血小板藥物和抗凝血劑到溶栓劑和神經保護藥物等各種藥物。大量的研發資金支持正在幫助拓展研發管道，新的療法旨在改善缺血性和出血性中風的療效。

缺血性中風是指腦血管阻塞引起的中風，在治療市場中佔主導地位。該領域在2024年創造了131億美元的市場規模，預計到2034年將達到285億美元，複合年成長率為8.1%。鑑於缺血性中風佔全球總病例的大多數，其需求趨勢仍然強勁。高膽固醇、心房顫動和糖尿病等誘發疾病的盛行率不斷上升，持續推動更有效治療的需求。藥物創新，尤其是在溶栓治療和抗血小板藥物研發方面的創新，正在幫助提高存活率和復原效果。

依年齡層細分，60歲以上族群佔比最高，到2024年將達46.8%。由於血管健康狀況下降和常見的合併症，中風風險會隨著年齡成長而顯著增加。老化也會影響神經血管反應性，因此老年人是治療介入的關鍵族群。醫療基礎設施的持續改善和以年齡為中心的健康計劃預計將使該細分市場持續成長至2034年。

2024年，美國中風治療市場規模達65億美元，這得益於先進的醫療體系、高強度的研發投入以及強大的製藥實力。包括幹細胞療法和基於人工智慧的診斷整合在內的快速創新鞏固了美國的領先地位。精準醫療和數位健康平台的日益關注，進一步增強了早期發現能力，並提高了治療效果。公共部門和私營部門的密切合作正在推動臨床試驗和產品線開發的擴展。

魯賓、輝瑞、勃林格殷格翰、賽諾菲、基因泰克、諾華、拜耳、阿斯特捷利康、第一三共、強生服務、Cadrenal Therapeutics、Prestige Consumer Healthcare、默克、衛材和百時美施貴寶等主要公司正在採取積極的成長策略。這些策略包括擴大臨床產品線、建立研發合作關係、爭取突破性藥物的監管批准，以及探索個人化醫療以提供標靶治療。許多公司投資於人工智慧平台和生物製劑創新，以最佳化治療方案和患者療效。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 中風發生率上升
    • 藥物研發進展
    • 提高認知和早期診斷
    • 中風研究投資和政府資助不斷增加
  • 產業陷阱與挑戰
    • 嚴格的法規核准
    • 副作用和安全問題
• 成長潛力分析
• 監管格局
• 管道分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：依中風類型，2021 年至 2034 年

• 主要趨勢
• 缺血性中風
• 出血性中風
• 其他中風類型

第6章：市場估計與預測：依藥物類別，2021 年至 2034 年

• 主要趨勢
• 組織纖溶酶原活化劑（TPA）
• 抗血小板藥物
• 抗凝血劑
• 其他藥物類別

第7章：市場估計與預測：依年齡層，2021 年至 2034 年

• 主要趨勢
• 40歲以下
• 41-59
• 60歲以上

第8章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院和診所
• 門診手術中心（ASC）
• 復健中心
• 研究和學術機構

第9章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• AstraZeneca
• Bayer
• Boehringer Ingelheim
• Bristol-Myers Squibb (BMS)
• Cadrenal Therapeutics
• Daiichi Sankyo
• Eisai
• Genentech
• Johnson & Johnson Services
• Lupin
• Merck
• Novartis
• Pfizer
• Prestige Consumer Healthcare
• Sanofi

The Global Stroke Therapeutics Market was valued at USD 16.6 billion in 2024 and is estimated to grow at a CAGR of 8.2% to reach USD 36.4 billion by 2034, fueled by the rising elderly population, coupled with increased prevalence of risk factors like obesity, hypertension, sedentary lifestyles, and chronic illnesses such as diabetes. An aging demographic is especially susceptible to stroke, leading to greater demand for advanced pharmaceutical treatments. At the same time, increased public health awareness and stronger government initiatives around early diagnosis and prevention are accelerating the adoption of therapeutics.

Pharmaceutical firms invest in research and development, focusing on novel biologics, gene therapies, and targeted drugs designed to improve clinical outcomes. Personalized medicine is becoming a key area of interest, allowing for more precise and effective treatment approaches. Stroke therapeutics includes medications, from antiplatelet agents and anticoagulants to thrombolytics and neuroprotective drugs. Substantial financial backing for R&D is helping expand the development pipeline, with new therapies aimed at improving outcomes for both ischemic and hemorrhagic stroke types.

Ischemic stroke, which occurs when a blood vessel to the brain is blocked, dominates the therapeutic market. This segment generated USD 13.1 billion in 2024 and is forecasted to hit USD 28.5 billion by 2034, growing at a CAGR of 8.1%. Given that ischemic strokes account for the majority of total cases globally, this demand trajectory remains strong. The rising prevalence of contributing conditions like high cholesterol, atrial fibrillation, and diabetes continues to push the need for more effective treatments. Drug innovations, especially in thrombolytic therapy and antiplatelet development, are helping improve survival rates and recovery outcomes.

When segmented by age group, individuals aged 60 and above have the largest share at 46.8% in 2024. The risk of stroke significantly increases with age due to declining vascular health and common comorbidities. Aging also affects neurovascular responsiveness, making seniors a key demographic for therapeutic intervention. The ongoing improvement of healthcare infrastructure and age-focused health initiatives are expected to sustain segment growth through 2034.

United States Stroke Therapeutics Market was valued at USD 6.5 billion in 2024, supported by advanced healthcare systems, high R&D intensity, and strong pharmaceutical presence. Rapid innovations, including stem cell therapies and AI-based diagnostic integration, reinforce the country's leadership. The growing focus on precision medicine and digital health platforms is further enhancing early detection and improving treatment efficacy. Robust public and private sector collaboration is fueling the expansion of clinical trials and pipeline development.

Key players such as Lupin, Pfizer, Boehringer Ingelheim, Sanofi, Genentech, Novartis, Bayer, AstraZeneca, Daiichi Sankyo, Johnson & Johnson Services, Cadrenal Therapeutics, Prestige Consumer Healthcare, Merck, Eisai, and Bristol-Myers Squibb are adopting aggressive growth strategies. These include expanding clinical pipelines, forming R&D partnerships, pursuing regulatory approvals for breakthrough drugs, and exploring personalized medicine to deliver targeted therapies. Many invest in AI platforms and biologics innovation to optimize treatment delivery and patient outcomes.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising stroke incidence cases
    • 3.2.1.2 Advancement in drug development
    • 3.2.1.3 Growing awareness and early diagnosis
    • 3.2.1.4 Rising investment in stroke research and government funding
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Strict regulatory approvals
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Stroke Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Ischemic stroke
• 5.3 Hemorrhagic stroke
• 5.4 Other stroke types

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Tissue plasminogen activators (TPA)
• 6.3 Antiplatelet agents
• 6.4 Anticoagulants
• 6.5 Other drug classes

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Below 40
• 7.3 41-59
• 7.4 above 60

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Ambulatory surgical centers (ASCs)
• 8.4 Rehabilitation centers
• 8.5 Research and academic institutions

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AstraZeneca
• 10.2 Bayer
• 10.3 Boehringer Ingelheim
• 10.4 Bristol-Myers Squibb (BMS)
• 10.5 Cadrenal Therapeutics
• 10.6 Daiichi Sankyo
• 10.7 Eisai
• 10.8 Genentech
• 10.9 Johnson & Johnson Services
• 10.10 Lupin
• 10.11 Merck
• 10.12 Novartis
• 10.13 Pfizer
• 10.14 Prestige Consumer Healthcare
• 10.15 Sanofi